Free Newsletter
Under settlement, FDA has to pre-approve Merck ads
One feature of Merck and Schering-Plough's settlement with 35 state attorneys general is a provision requiring the companies to get FDA to bless all its DTC advertisements--not just those for Vytorin, the cholesterol med that prompted the probe--before airing or publishing them. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: